CD276 and sarcoma: Finally, we investigated the efficacy of our B7-H3-targeting mAbs in comparative analyses of 8H8_SDIE versus 8H8_WT and respective controls to induce NK reactivity against sarcoma cells derived from patients diagnosed with liposarcoma, chondrosarcoma, rhabdomyosarcoma, osteosarcoma or synovial sarcoma.